|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Coronado Biosciences Announces Initiation of Investigator-Initiated Study Evaluating TSO in Ulcerative Colitis
8/7/2012 9:43:40 AM
BURLINGTON, Mass., Aug. 7, 2012 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today the initiation of an Investigator-Initiated Study (IIS) evaluating TSO (Trichuris suis ova or CNDO-201) for the treatment of ulcerative colitis (UC). The Study is being conducted by the NYU School of Medicine. Dr. Michael A. Poles, Associate Professor of Medicine, Gastroenterology, Microbiology and Pathology and Dr. P'ng Loke, Assistant Professor, Microbiology, from the NYU School of Medicine, are the Principal Investigators of the trial. Dr. Loke has acted as a scientific advisor to the company and in this role has received minimal compensation for his services.
|
|
|
|
|
|
|
|
|
|
|